Healthcare
Tuesday, January 31, 2017
BRIEF-European Commission approves Keytruda for first-line treatment of patients with metastatic non-small cell lung cancer
* European Commission approves Keytruda (pembrolizumab) for
first-line treatment of patients with metastatic non-small cell
lung cancer (NSCLC) whose tumors have high PD-l1 expression with
no EGFR or ALK positive tumor mutations
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment